Each shareholder has a say in our direction, including deciding on whether Tesla should be allowed to do a 3:1 stock split.
— Tesla (@Tesla) July 6, 2022
Incyte To Acquire Escient And Its Assets For $750M Plus Escient’s Net Cash Remaining At The Close Of The Transaction, Subject To Customary Adjustments
Incyte (NASDAQ:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a
